Clinical trials: HAIC
Hepatocellular Carcinoma, Transarterial Chemoembolization
TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 Trial
Hepatocellular carcinoma (HCC) is one of the most commonly malignant tumors around the world. Hepatic resection or liver transplantation is the radical method to cure the disease.
- Trial name
- Thalen (NCT04531228)
- Testing
- TACE-HAIC plus lenvatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Yunfei Yuan